Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

Watch livestream coverage from KPRC 2 Click2Houston.In between live newscasts and events, you'll see highlights from KPRC 2 News: KPRC 2 News Today: Weekdays 5 a.m. - 7 a.m.; Saturdays at 6 a.m ...

As the successor to the Nintendo Switch console, the Nintendo Switch 2 will feature a large library of games that can be played both in handheld mode and from ...

Nintendo sold 1.6 million Switch 2 consoles in June 2025 Nintendo Switch 2 becomes fastest-selling game console in US history Sony's 12-year reign has ended PlayStation 5 remains 2025 's best-selling ...

The Global Selective Estrogen Receptor Degrader (SERD) Market is rapidly evolving, highlighted by key innovations like FDA-approved Orserdu and the u ...

Vampire: The Masquerade – Bloodlines 2 Exclusive Coverage Vampire: The Masquerade – Bloodlines 2 Cover Story Twenty years after the release of this cult classic RPG, The Chinese Room is reviving the ...

VERITAC-2 was the first head-to-head study to compare the efficacy and safety of vepdegestrant with the intramuscular SERD fulvestrant in patients with advanced ER+/HER2- BC after combination CDK4/6 ...

Early diagnosis of type 2 diabetes can help prevent complications. Learn about the tests doctors use to diagnose the condition.